Kristina M. Angelo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristina M. Angelo has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Allison T Walker
Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention , 1600 Clifton Rd NE, Atlanta, GA 30329
2 shared publicationsBradley A Connor
New York Center for Travel and Tropical Medicine , 110 E 55th St, New York, NY 10022
2 shared publicationsCharandeep Waraich
New York Center for Travel and Tropical Medicine , 110 E 55th St, New York, NY 10022
2 shared publicationsEdward Ryan
Division of Infectious Diseases, Massachusetts General Hospital , 55 Fruit St, Boston, MA 02114
2 shared publicationsElizabeth Oliver
Division of Infectious Diseases, Massachusetts General Hospital , 55 Fruit St, Boston, MA 02114
2 shared publicationsGraeme Prentice-Mott
Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention , 1600 Clifton Rd NE, Atlanta, GA 30329
2 shared publications
Latest Publications
- 29 May 2025
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 32 (6)
Efficacy of bismuth subsalicylate on the prevention of travellers′ diarrhoea, 2018–2023
Background: Travellers’ diarrhoea (TD) is the most common travel-related illness. Bismuth subsalicylate (BSS) is indicated for the treatment of TD. BSS is also used off-label for the prevention of TD, based on studies from the 1980s indicating TD protection; however, these studies have limitations. The objective of this study was to determine the efficacy of BSS in the prevention of TD. Methods: This study was a prospective, double-blinded, placebo-controlled, randomized clinical trial (NCT03535272) with two arms: BSS 4 tablets twice daily (2.1 grams of BSS total) vs placebo. Travellers were included if they were ≥ 18 and < 70 years of age at the time of enrollment, were leaving for an international trip ≥7 days after their pretravel consultation, travelling in country for ≥7 days but ≤ 21 days, and travelling to either Southeast Asia, South Central Asia, North Africa, or Sub-Saharan Africa. Self-completed web-based questionnaires were administered before, during, and after travel. Results: 270 participants were included. The median age was 32 years (Interquartile range [IQR]: 27–44); 63% were female. Travellers were most frequently White (144; 61%) and non-Hispanic (239; 94%). The most frequent country of travel was Kenya (n = 87; 32%). The median total trip duration was 10 days ([IQR]: 8–13). The most frequent reason for travel was leisure/tourism (230, 85%). There was no significant difference among the groups for symptoms of loose stool and/or diarrhoea, although target sample size was not reached. Conclusions: This study provides the first new data since the 1980s about the potential use of BSS in the prevention of TD. These data should not be viewed as evidence in isolation because of sample size constraints; further studies are needed to determine if there is a benefit in certain traveller groups or under certain circumstances.
- 29 May 2025
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 32 (6)
Efficacy of bismuth subsalicylate on the prevention of travellers′ diarrhoea, 2018–2023
Background: Travellers’ diarrhoea (TD) is the most common travel-related illness. Bismuth subsalicylate (BSS) is indicated for the treatment of TD. BSS is also used off-label for the prevention of TD, based on studies from the 1980s indicating TD protection; however, these studies have limitations. The objective of this study was to determine the efficacy of BSS in the prevention of TD. Methods: This study was a prospective, double-blinded, placebo-controlled, randomized clinical trial (NCT03535272) with two arms: BSS 4 tablets twice daily (2.1 grams of BSS total) vs placebo. Travellers were included if they were ≥ 18 and < 70 years of age at the time of enrollment, were leaving for an international trip ≥7 days after their pretravel consultation, travelling in country for ≥7 days but ≤ 21 days, and travelling to either Southeast Asia, South Central Asia, North Africa, or Sub-Saharan Africa. Self-completed web-based questionnaires were administered before, during, and after travel. Results: 270 participants were included. The median age was 32 years (Interquartile range [IQR]: 27–44); 63% were female. Travellers were most frequently White (144; 61%) and non-Hispanic (239; 94%). The most frequent country of travel was Kenya (n = 87; 32%). The median total trip duration was 10 days ([IQR]: 8–13). The most frequent reason for travel was leisure/tourism (230, 85%). There was no significant difference among the groups for symptoms of loose stool and/or diarrhoea, although target sample size was not reached. Conclusions: This study provides the first new data since the 1980s about the potential use of BSS in the prevention of TD. These data should not be viewed as evidence in isolation because of sample size constraints; further studies are needed to determine if there is a benefit in certain traveller groups or under certain circumstances.
- 24 February 2021
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 40, 101999
Health problems in travellers to Nepal visiting CIWEC clinic in Kathmandu — A GeoSentinel analysis
- 24 February 2021
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 40, 101999
Health problems in travellers to Nepal visiting CIWEC clinic in Kathmandu — A GeoSentinel analysis